Biofrontera Inc (BFRI)vsUnited Therapeutics Corporation (UTHR)
BFRI
Biofrontera Inc
$0.94
-6.03%
HEALTHCARE · Cap: $13.19M
UTHR
United Therapeutics Corporation
$549.87
+0.40%
HEALTHCARE · Cap: $23.17B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 7237% more annual revenue ($3.17B vs $43.20M). UTHR leads profitability with a 40.6% profit margin vs -25.7%. UTHR earns a higher WallStSmart Score of 57/100 (C).
BFRI
Avoid33
out of 100
Grade: F
UTHR
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BFRI.
Margin of Safety
+2.5%
Fair Value
$487.82
Current Price
$549.87
$62.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
17.4% revenue growth
Keeps 41 of every $100 in revenue as profit
Strong operational efficiency at 41.7%
Safe zone — low bankruptcy risk
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
Expensive relative to growth rate
Revenue declined 1.6%
Earnings declined 12.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : BFRI
The strongest argument for BFRI centers on Price/Book, Revenue Growth. Revenue growth of 17.4% demonstrates continued momentum.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 40.6% and operating margin at 41.7%.
Bear Case : BFRI
The primary concerns for BFRI are EPS Growth, Market Cap, Debt/Equity.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
BFRI profiles as a growth stock while UTHR is a declining play — different risk/reward profiles.
BFRI carries more volatility with a beta of 0.91 — expect wider price swings.
BFRI is growing revenue faster at 17.4% — sustainability is the question.
UTHR generates stronger free cash flow (363M), providing more financial flexibility.
Bottom Line
UTHR scores higher overall (57/100 vs 33/100), backed by strong 40.6% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Biofrontera Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Biofrontera Inc., a biopharmaceutical company, develops and supplies dermatological products for the treatment of skin conditions in the United States. The company is headquartered in Woburn, Massachusetts.
United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?